The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.
Besifovir dipivoxil maleate has antiviral efficacy against chronic hepatitis B that is similar to that of tenofovir disoproxil fumarate but with a lower impact on bone and renal safety, as shown in the results of a phase III trial involving Asian patients.
The investigational first-in-class attachment inhibitor prodrug fostemsavir (FTR) continues to improve virologic and immunologic response from weeks 48 to 96 in patients with multidrug-resistant HIV-1 who had been heavily treated, according to the BRIGHTE* study presented at IAS 2019.
Individuals with HIV-1 who demonstrate virologic suppression on a tenofovir alafenamide fumarate (TAF)-based three- or four-drug regimen (TBR) could safely switch to a two-drug regimen comprising dolutegravir and lamivudine, according to results from the phase III TANGO* study presented at the recent International AIDS Society conference (IAS 2019).
Individuals with obesity are at an elevated risk of developing infections, particularly that of the skin in both men and women, and those of the gastrointestinal and urinary tracts and sepsis in women only, according to a study.
The PRoFeSs score―which includes the Charlson score, as well as levels of day 3 lactate, day 1 and day 3 procalcitonin, day 3 D-dimer, and day 1 brain-type natriuretic peptide―can identify severe community-acquired pneumonia patients at high risk of poor outcomes 5 days after ICU admission, a recent study has found.
There is a steady annual growth in the incidence rate of syphilis in men living with HIV, according to a new Singapore study. Rates are consistently higher among men who have sex with men (MSM) than their heterosexual counterparts.
The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.